Global Mouth Ulcers Treatment Market, Forecast Till 2025

  • Category : Healthcare and Pharma
  • |
  • ID : 794900
  • |
  • Publishe Date : February 2019
  • |
  • No of Pages: 121
  • |
  • Publisher : Intellectual Research Partners

The Global Mouth Ulcers Treatment Market was valued at USD XX million in 2017, and is expected to grow at a CAGR of XX% by 2025. Rising awareness regarding oral hygiene and increasing geriatric population is anticipated to drive the market during the forecast period.

Higher prevalence of mouth ulcers, increasing disease and treatment awareness, rising adoption of pharmaceuticals as a treatment option and a significant rise in the count of geriatric population in the market are the factors driving the growth of the Mouth Ulcers Treatment market.

Factors, such as presence of substitute traditional treatments and limited accessibility to pharmaceuticals in developing countries are likely to hinder the market growth.

Lucrative growth in mouth ulcer treatment market is expected in Asia-Pacific region due to rising health awareness and cost-effective treatment procedures.

On the basis of drug class, the market is segmented into antimicrobial, antihistamine, analgesics & corticosteroids, and others. Analgesics and corticosteroids are likely to witness the highest CAGR during the same period, as they are the most prescribed pain killers in the global market

On the basis of formulation, the mouth ulcers treatment market is divided into sprays, mouthwash, gels, and lozenges.

Regionally North America market is anticipated to dominate the Mouth ulcers treatment market due to the technological advancement in the diagnostic procedures of oral and dental care.

Some of the key players operating in this market include Blistex Inc.; Church & Dwight Co, Inc.; 3M; Colgate Palmolive Company; GlaxoSmithKline, Plc; and Bristol-Myers Squibb Company.

Key Benefits of the Report:
* Global, Regional, Country, Drug Class, and Route of Formulation Market Size and Forecast from 2014-2025
* Detailed market dynamics, industry outlook with market specific PESTLE, Value Chain, Supply Chain, and SWOT Analysis to better understand the market and build strategies
* Identification of key companies that can influence this market on a global and regional scale
* Expert interviews and their insights on market shift, current and future outlook and factors impacting vendors short term and long term strategies
* Detailed insights on emerging regions, Drug Class& Formulation, and competitive landscape with qualitative and quantitative information and facts

Target Audience:
* Mouth Ulcers Treatment providers
* Traders, Importer and Exporter
* Raw material suppliers and distributors
* Research and consulting firms
* Government and research organizations
* Associations and industry bodies

Research Methodology

The market is derived through extensive use of secondary, primary, in-house research followed by expert validation and third party perspective like analyst report of investment banks. The secondary research forms the base of our study where we conducted extensive data mining, referring to verified data sources such as white papers government and regulatory published materials, technical journals, trade magazines, and paid data sources.

For forecasting, regional demand & supply factor, investment, market dynamics including technical scenario, consumer behavior, and end use industry trends and dynamics , capacity Formulation, spending were taken into consideration.

We have assigned weights to these parameters and quantified their market impacts using the weighted average analysis to derive the expected market growth rate.

The market estimates and forecasts have been verified through exhaustive primary research with the Key Industry Participants (KIPs) which typically include:
* Original Manufacturer,
* Drug Class Supplier,
* Distributors,
* Government Body & Associations, and
* Research Institute
* Pharmacies

TABLE OF CONTENT

1 EXECUTIVE SUMMARY

2 METHODOLOGY AND MARKET SCOPE
2.1 Research Methodology
2.2 Research Scope & Assumptions

3 MOUTH ULCERS TREATMENT MARKET — INDUSTRY OUTLOOK
3.1 Market Segmentation and Scope
3.2 Market Size & Growth Prospects
3.3 Mouth Ulcers Treatment Market — Value Chain / Supply Chain Analysis
3.3.1 Company Landscape
3.4 Mouth Ulcers Treatment Market — Market Dynamics
3.4.1 Market Driver
3.4.2 Market Restraints
3.4.3 Market Challenges
3.5 Mouth Ulcers Treatment Market Company Market Share, 2017
3.6 Mouth Ulcers Treatment Market — Porter\'s Five Forces Analysis
3.7 Mouth Ulcers Treatment Market — Pestel Analysis

4 MOUTH ULCERS TREATMENT MARKET DRUG CLASS OUTLOOK
4.1 Mouth Ulcers Treatment Market Share by Drug Class, 2016 & 2025
4.2 Antimicrobial
4.3 Antihistamine
4.4 Analgesics & Corticosteroids
4.5 Others

5 MOUTH ULCERS TREATMENT MARKET FORMULATION OUTLOOK
5.1 Mouth Ulcers Treatment Market Share by Formulation, 2016 & 2025
5.2 Sprays
5.3 Mouthwash
5.4 Lozenges
5.5 Gels

6 MOUTH ULCERS TREATMENT MARKET REGIONAL OUTLOOK
6.1 Mouth Ulcers Treatment Market Share by Region, 2016 & 2025
6.2 North America
6.2.1 North America Mouth Ulcers Treatment Market, 2014 - 2025
6.2.2 North America Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.2.3 North America Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.2.5 U.S.
6.2.5.1 U.S. Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.2.5.2 U.S. Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.2.6 Canada
6.2.6.1 Canada Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.2.6.2 Canada Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.3 Europe
6.3.1 Europe Mouth Ulcers Treatment Market, 2014 - 2025
6.3.2 Europe Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.3.3 Europe Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.3.5 Germany
6.3.5.1 Germany Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.3.5.2 Germany Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.3.6 UK
6.3.6.1 UK Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.3.6.2 UK Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.4 Asia Pacific
6.4.1 Asia Pacific Mouth Ulcers Treatment Market, 2014 - 2025
6.4.2 Asia Pacific Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.4.3 Asia Pacific Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.4.5 Australia
6.4.5.1 Australia Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.4.5.2 Australia Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.4.6 New Zealand
6.4.6.1 New Zealand Mouth Ulcers Treatment Market, By Drug Class, 2014 -
2025
6.4.6.2 New Zealand Mouth Ulcers Treatment Market, By Formulation, 2014 -2025
6.4.7 China
6.4.7.1 China Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.4.7.2 China Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.4.8 India
6.4.8.1 India Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.4.8.2 India Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.4.9 Japan
6.4.9.1 Japan Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.4.9.2 Japan Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.5 South America
6.5.1 South America Mouth Ulcers Treatment Market, 2014 - 2025
6.5.2 South America Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.5.3 South America Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.5.5 Brazil
6.5.5.1 Brazil Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.5.5.2 Brazil Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.5.6 Mexico
6.5.6.1 Mexico Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.5.6.2 Mexico Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025
6.6 MEA
6.6.1 MEA Mouth Ulcers Treatment Market, 2014 - 2025
6.6.2 MEA Mouth Ulcers Treatment Market, By Drug Class, 2014 - 2025
6.6.3 MEA Mouth Ulcers Treatment Market, By Formulation, 2014 - 2025

7 COMPETITIVE LANDSCAPE
7.1 Blistex Inc
7.1.2 Financial performance
7.1.3 Drug Class benchmarking
7.1.4 Strategic initiatives
7.2 Church & Dwight Co, Inc
7.2.1 Company overview
7.2.2 Financial performance
7.2.3 Drug Class benchmarking
7.2.4 Strategic initiatives
7.3 3M
7.3.1 Company overview
7.3.2 Financial performance
7.3.3 Drug Class benchmarking
7.3.4 Strategic initiatives
7.4 Colgate Palmolive Company
7.4.1 Company overview
7.4.2 Financial performance
7.4.3 Drug Class benchmarking
7.4.4 Strategic initiatives
7.5 GlaxoSmithKline, Plc
7.5.1 Company overview
7.5.2 Financial performance
7.5.3 Drug Class benchmarking
7.5.4 Strategic initiatives
7.6 Bristol-Myers Squibb Company
7.6.1 Company overview
7.6.2 Financial performance
7.6.3 Drug Class benchmarking
7.6.4 Strategic initiatives
7.7 ECR Pharmaceuticals Co. Inc
7.7.1 Company overview
7.7.2 Financial performance
7.7.3 Drug Class benchmarking
7.7.4 Strategic initiatives

End of the report
Disclaimer.

Content are not available

Choose License Type